CV Sciences files motion to dismiss CBD lawsuit: ‘This case is pre-empted’

By Elaine Watson contact

- Last updated on GMT

CV Sciences is one of a handful of companies to have put together GRAS determinations for its hemp extracts. Picture: CV Sciences
CV Sciences is one of a handful of companies to have put together GRAS determinations for its hemp extracts. Picture: CV Sciences

Related tags: Cbd

In a motion to dismiss a lawsuit* filed in California accusing it of selling ‘illegal’ CBD-infused products, PlusCBD Oil maker CV Sciences deploys multiple arguments: no one was harmed; plaintiffs lack standing to seek label changes; the case is pre-empted by federal law; and if it’s not immediately tossed, it should be stayed until the FDA formally clarifies its position on CBD.

It does not, however, make the argument that its full spectrum hemp extracts are legal dietary ingredients because they are a different article to the isolated CBD used in drug trials, a case recently made by supplement brand Diamond CBD​ ​and something CV Sciences execs have argued in other settings (notably the May 2019 FDA hearing​).

Instead, CV Sciences focuses on more basic legal arguments, arguing first and foremost that federal pre-emption applies: “Plaintiffs cannot escape the preemptive effect of the Food, Drug and Cosmetic Act.

“Their claims arise solely from the alleged failure of the product to meet the Act’s statutory definition of a Dietary Supplement… As a result, all of the state law claims Plaintiffs assert here are preempted.”

Moreover, its attorneys note: “Neither plaintiff was harmed by the product, nor did the product’s label misrepresent its actual contents; plaintiffs paid for a CBD product and received exactly that product... Plaintiffs​ [also] lack standing to seek injunctive relief. Therefore, any claim that seeks such a remedy must be dismissed as a jurisdictional matter​.”

‘Until the agency establishes the rules that will govern CBD products, the court should stay this litigation’

Finally, echoing arguments​ made by multiple CBD firms hit with lawsuits, they say the case should be stayed (put on hold) on primary jurisdiction grounds given that the FDA is actively considering​ how to regulate the CBD marketplace (ie. it would be unwise for courts to make local determinations now as the relevant federal agency is poised to act).

Until the agency establishes the rules that will govern CBD products, the court should stay this litigation… While Plaintiffs allege that the FDA has sent warning letters to companies selling CBD products about labels pertaining to the designation as a dietary supplement, those letters are not final agency action, and the FDA’s final position is not yet established.”


Hemp-derived CBD: Navigating the regulatory minefield

The FDA has promised to provide more clarity over CBD “in the coming weeks.​” But how should brands navigate the regulatory minefield in the meantime, and what options does the agency have?

WATCH our video​ with PSL Law Group partner Jeni Lamb Rogers.

Charlotte’s Web – another leading player in the hemp-derived supplements arena to be hit with a lawsuit - not yet filed a motion to dismiss, but several other players have cited a recent court ruling in Florida that stayed a CBD-related class action (Snyder et al v Green Roads of Florida​**) on primary jurisdiction grounds.

*Colette and Shaw el at, v CV Sciences 2:19-cv-10227

***Snyder et al v Green Roads of Florida LLC 0:19-cv-62342

Related topics: Manufacturers, CBD / Hemp, Botanicals

Related news

Related products

show more

Unlike Any Other Turmeric

Unlike Any Other Turmeric

Applied Food Sciences | 12-Feb-2020 | Technical / White Paper

As consumers are craving complex flavors, bright colors, and more transparent labels, Applied Food Sciences is bringing this golden-yellow spice to products...



SABINSA | 03-Feb-2020 | Technical / White Paper

Healthy proteins from the plant world are muscling in on the massive protein powder market, offering a host of ethical, sustainable and vegan options to...

Related suppliers


Post your comment

We will not publish your email address on the website

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.

Follow us

Featured Events

View more


View more